We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+1.09%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+879.75%
AUM
$50.8B
AUM Growth
-$294M
(-0.58%)
Cap. Flow
-$328M
Cap. Flow
% of AUM
-0.65%
Top 10 Holdings %
Top 10 Hldgs %
22.21%
Holding
1,137
New
127
Increased
273
Reduced
442
Closed
122
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$255M |
| 2 |
Textron
TXT
|
+$206M |
| 3 |
AstraZeneca
AZN
|
+$164M |
| 4 |
ExxonMobil
XOM
|
+$124M |
| 5 |
Moderna
MRNA
|
+$121M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$962M |
| 2 |
WORK
Slack Technologies, Inc.
WORK
|
+$204M |
| 3 |
Devon Energy
DVN
|
+$201M |
| 4 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$170M |
| 5 |
Carrier Global
CARR
|
+$155M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.3% |
| 2 | Healthcare | 15.98% |
| 3 | Financials | 14.49% |
| 4 | Consumer Discretionary | 11.52% |
| 5 | Communication Services | 8.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EQOS
876
DELISTED
EQONEX LIMITED Ordinary Shares
EQOS
| $2.66M | 0.01% |
819,875
+113,991
| +16% | +$579K |
|
877
Standard BioTools
LAB
$307M
| $2.64M | 0.01% |
+400,000
| New | +$2.63M |
|
|
IAS
878
DELISTED
Integral Ad Science
IAS
| $2.63M | 0.01% |
127,668
-572,332
| -82% | -$11.3M |
|
|
CFRX
879
DELISTED
ContraFect Corporation
CFRX
| $2.63M | 0.01% |
8,125
| – | – |
|
880
Phathom Pharmaceuticals
PHAT
$666M
| $2.62M | 0.01% |
81,600
| – | – |
|
881
Arcus Biosciences
RCUS
$3.48B
| $2.62M | 0.01% |
75,000
| – | – |
|
882
Delcath Systems
DCTH
$436M
| $2.61M | 0.01% |
250,000
| – | – |
|
|
ITOS
883
DELISTED
iTeos Therapeutics
ITOS
| $2.56M | 0.01% |
95,000
+38,107
| +67% | +$996K |
|
884
Eledon Pharmaceuticals
ELDN
$266M
| $2.53M | 0.01% |
409,759
-443,449
| -52% | -$3.1M |
|
|
SEI
885
Solaris Energy Infrastructure
SEI
$3.41B
| $2.52M | 0.01% |
302,430
-15,000
| -5% | -$122K |
|
|
BLU
886
DELISTED
BELLUS Health Inc.
BLU
| $2.46M | ﹤0.01% |
400,000
-1,000,000
| -71% | -$3.79M |
|
887
Design Therapeutics
DSGN
$849M
| $2.42M | ﹤0.01% |
165,000
+119,888
| +266% | +$1.99M |
|
|
MREO
888
Mereo BioPharma
MREO
$48.4M
| $2.42M | ﹤0.01% |
+1,000,000
| New | +$2.65M |
|
889
CS Disco
LAW
$260M
| $2.4M | ﹤0.01% |
+50,000
| New | +$2.53M |
|
890
T. Rowe Price
TROW
$24.5B
| $2.26M | ﹤0.01% |
11,504
-19,500
| -63% | -$4.11M |
|
891
Evercore
EVR
$12.3B
| $2.19M | ﹤0.01% |
16,363
| – | – |
|
|
DAWN
892
DELISTED
Day One Biopharmaceuticals
DAWN
| $2.14M | ﹤0.01% |
+90,000
| New | +$2.16M |
|
893
Novavax
NVAX
$1.27B
| $2.07M | ﹤0.01% |
+10,000
| New | +$2.2M |
|
894
Larimar Therapeutics
LRMR
$426M
| $2.04M | ﹤0.01% |
176,680
+100,000
| +130% | +$1.2M |
|
895
Wave Life Sciences
WVE
$1.17B
| $1.96M | ﹤0.01% |
+400,000
| New | +$2.43M |
|
896
Eastern Bankshares
EBC
$5.31B
| $1.84M | ﹤0.01% |
90,493
-62,520
| -41% | -$1.2M |
|
897
Leggett & Platt
LEG
$1.4B
| $1.82M | ﹤0.01% |
+40,600
| New | +$1.96M |
|
898
DocGo
DCGO
$62M
| $1.82M | ﹤0.01% |
182,286
-482,176
| -73% | -$4.79M |
|
|
CAS
899
DELISTED
Cascade Acquisition Corp.
CAS
| $1.73M | ﹤0.01% |
173,050
| – | – |
|
|
RETA
900
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $1.71M | ﹤0.01% |
+17,000
| New | +$1.99M |
|
Similar funds
Adage Capital Partners's Q3 2021 Portfolio in Review
As of Q3 2021, Adage Capital Partners held 1,137 positions worth $50.8B, down 0.58% from $51.1B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Adage Capital Partners's Q3 2021 filing shows 127 new, 273 increased, 442 reduced and 122 closed positions. Its largest new stake was Pfizer: 5,759,101 shares worth $248M. The largest sale was Alexion Pharmaceuticals, an estimated $962M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 22% a quarter earlier, followed by Healthcare and Financials.
- Adage Capital Partners's largest Q3 2021 buy was Pfizer: 5,759,101 shares worth $248M.
- Adage Capital Partners added most to Textron in Q3 2021, an estimated $206M increase.
- Adage Capital Partners's biggest Q3 2021 reduction was Devon Energy, cutting an estimated $201M.
- Adage Capital Partners fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $962M.
- Adage Capital Partners's ten largest holdings make up 22% of its $50.8B portfolio in Q3 2021.
- Adage Capital Partners opened 127 new positions and closed 122 in Q3 2021.
- Adage Capital Partners's portfolio value fell 0.58% quarter-over-quarter to $50.8B.
Based on Adage Capital Partners's 13F filing for Q3 2021, filed 15 Nov 2021.